Navigation Links
Frost & Sullivan Honours GELITA for Developing European Health Ingredient of the Year
Date:11/11/2008

MOUNTAIN VIEW, Calif., Nov. 11 /PRNewswire/ -- The 2008 Frost & Sullivan European Health Ingredient of the Year Award is presented to GELITA AG in recognition of its pioneering efforts in developing the novel ingredient FORTIGEL(R) to treat joint health problems.

"Rather than cure, current medical treatments for osteoarthritis only address the symptoms such as inflammation and pain," notes Frost & Sullivan Research Analyst Kaushik Ghosh. "FORTIGEL(R) represents the first ingredient in both the food and drug industries, which can actually result in cartilage rejuvenation, thus providing a practical treatment for osteoarthritis."

Manufactured through a special enzymatic process, FORTIGEL(R) is a specially purified protein containing 'bioactive collagen peptides(R)' (protein of the connective tissue in animals). A pure protein, FORTIGEL(R) effectively combats the wear and tear of joints brought about by age and stress.

FORTIGEL(R) does not contain gluten, purine, tryptophan, GMO and cholesterol, and thus is not associated with the risk of any allergy or side effects. Its neutral taste and odour, coupled with its excellent solubility, make it ideal for fortification in a variety of food products. Being a natural ingredient, FORTIGEL(R) is ideally aligned with the 'health and wellness' trend in the food industry.

"FORTIGEL(R) is also characterised by a high degree of bio availability, which ensures value-chain feasibility for food manufacturers," remarks Ghosh. "Thus, food products containing FORTIGEL(R) can safely be positioned for joint pain arising due to osteoarthritis, obesity, old age and sports activities."

FORTIGEL(R) has also been approved by the FDA with the Generally Recognized As Safe (GRAS) status on account of its proven health benefits and safety parameters. It also currently represents the only ingredient to be authorised by the Collagen Research Institute (CRI), Germany. It has been certified by the International Organisation for Standardisation (ISO) as well as by the Hazard Analysis and Critical Control Points (HACCP) process.

"The USP of FORTIGEL(R) is the complete set of clinical data that provides testimony of its efficiency in the joint health segment," states Ghosh. "Meticulous research spanning three decades has yielded authentic evidence supporting FORTIGEL(R)'s effectiveness in regenerating joint cartilage, improving mobility and reducing pain."

At present, FORTIGEL(R) is the only ingredient to have a 'cartilage regeneration' claim with solid proof to back it up. The company is currently analysing the effect of FORTIGEL(R) against osteoporosis and represents the only viable natural treatment for the condition.

Gelita has maintained a competitive price for its breakthrough ingredient FORTIGEL(R). Despite being the pioneer in this segment, the company has chosen to follow a 'price-to-value' strategy, rather than a premium pricing model. The competitive pricing of FORTIGEL(R) has made it an affordable alternative to more expensive traditional osteoarthritis treatments.

The Frost and Sullivan Award for Joint Health Ingredient of the Year is presented to the company that has demonstrated excellence in new ingredient development and launch within its industry. The recipient company has shown tremendous innovation by launching a broad line of emerging products and technologies.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Gelita AG

GELITA AG is the world's leading manufacturer of gelatine and collagen hydrolysate and maintains production facilities in Europe, North America, South America and the Asian-Pacific Basin. The group employs some 2800 people worldwide. Gelatine is a valuable collagenous protein that is used in the areas of foodstuffs, health/pharmaceuticals and photography. Products containing gelatine are e.g. gummy bears, cakes, aspic products, health bars, fitness beverages for joint nutrition, pharmaceutical capsules for vitamins and medication as well as classical photographic film, paper and special paper for ink-jet printers.

Media Contact: Michael Teppner, Corporate Communications Manager, Gelita AG, E: michael.teppner@gelita.com, P: 0049 6271 84 2190

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit http://www.frost.com.

Media Contact: Ciara Connolly, Senior Events & Promotions Executive, Best Practices Frost & Sullivan, P: 0044 (0) 207 915 7868, E: ciara.connolly@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Supernanny Jo Frost Joins the Partnership for a Drug-Free America in Supporting Time To Talk(TM)
2. Masimo Corporation Receives a Frost & Sullivan 2007 Industry Best Practices Award for Pulse Oximetry Leadership
3. Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award
4. Novadaqs SPY Imaging System named Product of the Year by Frost and Sullivan
5. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
6. Kelloggs Frosted Flakes Gold(TM) Helps Moms Get the Gold
7. MedApps Receives Prestigious Frost & Sullivan Award
8. Nancy Frost Joins Lawson-Hawks as Employee Benefits Vice President
9. Accurays CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan
10. Help Your Kids Earn an A for Attentiveness with a Bowl of Frosted Mini- Wheats(R) Cereal for Breakfast
11. Therapy Could Save Limbs After Frostbite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & Associates, a locally ... business owners in North Central West Virginia, is embarking on a cooperative charity ... residents in the region. , The Stepping Stones organization offers a series of ...
(Date:6/22/2017)... ... 2017 , ... Plastic Surgery Associates is proud to report that founding surgeon, ... research and information firm, Castle Connolly, releases their list of the most notable and ... 3rd time that Dr. Canales has been recognized by Castle Connolly. , ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... from the American Heart Association (AHA) to launch a Rheumatic Heart Disease Center, ... prevention and diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... announced today that it has received certification for ANSI/ASIS PSC.1-2012. The company’s work ... in environments where the rule of law has been degraded. The PSC.1 standard ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, ... a Nashville-based private equity firm, has invested $3.35 million in the company. ... and Claritas Capital offers the smart money, speed to market and accountability we ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... 2017  Eli Lilly and Company (NYSE: ... the Phase 3 MONARCH 2 study showed that ... in combination with fulvestrant, significantly improved progression-free survival ... women with hormone-receptor-positive (HR+), human epidermal growth factor ... relapsed or progressed after endocrine therapy (median PFS, ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology: